English
-
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
05/24/2024 - 05:12 AM
-
Barnes & Noble Education Announces Preliminary Fiscal Year 2024 Results
05/24/2024 - 05:10 AM
-
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
05/24/2024 - 05:10 AM
-
05/24/2024 - 05:06 AM
-
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
05/24/2024 - 05:05 AM
-
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
05/24/2024 - 05:05 AM
-
TelevisaUnivision Announces Pricing of $1.0 Billion Debt
05/24/2024 - 05:05 AM
-
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
05/24/2024 - 05:05 AM
-
05/24/2024 - 05:05 AM
-
BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Declares Distribution
05/24/2024 - 05:04 AM
-
KBRA Assigns AAA Rating, Stable Outlook to the New Mexico Finance Authority State Transportation Revenue Refunding Bonds (State Transportation Commission - Senior Lien), Series 2024A
05/24/2024 - 05:02 AM
-
Stellar Bancorp, Inc. Declares Quarterly Dividend and New Share Repurchase Program
05/24/2024 - 05:02 AM
-
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
05/24/2024 - 05:01 AM
-
05/24/2024 - 05:01 AM
-
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
05/24/2024 - 05:00 AM